Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants by Nemchinov, Lev G & Natilla, Angela
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Publications from USDA-ARS / UNL Faculty U.S. Department of Agriculture: Agricultural Research Service, Lincoln, Nebraska 
2007 
Transient expression of the ectodomain of matrix protein 2 (M2e) 
of avian influenza A virus in plants 
Lev G. Nemchinov 
United States Department of Agriculture 
Angela Natilla 
United States Department of Agriculture 
Follow this and additional works at: https://digitalcommons.unl.edu/usdaarsfacpub 
 Part of the Agricultural Science Commons 
Nemchinov, Lev G. and Natilla, Angela, "Transient expression of the ectodomain of matrix protein 2 (M2e) 
of avian influenza A virus in plants" (2007). Publications from USDA-ARS / UNL Faculty. 369. 
https://digitalcommons.unl.edu/usdaarsfacpub/369 
This Article is brought to you for free and open access by the U.S. Department of Agriculture: Agricultural Research 
Service, Lincoln, Nebraska at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in 
Publications from USDA-ARS / UNL Faculty by an authorized administrator of DigitalCommons@University of 
Nebraska - Lincoln. 
Transient expression of the ectodomain of matrix protein 2 (M2e)
of avian influenza A virus in plants
Lev G. Nemchinov *, Angela Natilla
Molecular Plant Pathology Laboratory, Plant Sciences Institute, United States Department of Agriculture, Agricultural Research Service,
10300 Baltimore Avenue, Beltsville, MD 20705, USA
Received 29 March 2007, and in revised form 4 May 2007
Available online 7 June 2007
Abstract
We have previously reported an expression system based on the capsid protein gene (CP) of cucumber mosaic virus (CMV) placed
under transcriptional control of a potato virus X (PVX)-based vector. PVX-expressed CMV CP formed virus-like particles, which served
as carriers for heterologous antigens of the Newcastle disease virus (NDV).
In this work, we applied our expression tool toward the development of plant-derived vaccine candidate against avian influenza A
virus. Twenty-three amino acid-long extracellular domain of the viral M2 protein (M2e) was engineered into the internal motif 5 of
CMV CP and the recombinant gene then was transiently expressed in plants through a PVX vector. Chimeric CMV capsids reacted with
specific antibodies produced to synthetic M2e epitope of the H5N1 strain of the virus. In addition, CMV CP-M2e protein was expressed
to high levels in Escherichia coli bacterial cells and was recognized by antibodies to both CMV and M2e. This initial study demonstrates
the feasibility of using plant virus-based vectors for expression of antigenic epitopes of H5N1 avian influenza in plants.
Published by Elsevier Inc.
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Influenza type A virus is classified into several subtypes
which vary in two of their transmembrane proteins, hemag-
glutinin (HA)1 and neuraminidase (NA) and possess simi-
lar nucleoprotein and matrix protein [1]. A constant
antigenic reassortment in surface-located HA and NA,
which are, respectively, responsible for binding of the virus
to its cellular receptor and promoting release of the mature
virus from infected cells [2], makes vaccine development a
complicated process. There are 16 known HA subtypes
and nine known NA subtypes of influenza A viruses and
many different combinations are possible. Three subtypes,
(H1N1, H1N2, and H3N2), commonly circulate among
humans and all known subtypes of influenza A viruses
can be found in birds [3]. Influenza A subtype H5N1 virus,
known as avian influenza or bird flu, is endemic mainly in
birds and does not usually infect people. However, because
of its high virulence, H5N1 may be transmitted from
infected birds to humans and cause fatal disease. The
cumulative number of laboratory-confirmed human cases
of avian influenza H5N1 reported to WHO by September
25, 2006 is 16 [4]. Currently, vaccines against influenza
viruses are produced each year after thorough global sur-
veillance, analyzing and prediction of the main circulating
strains. Vaccines normally include HA as a main compo-
nent of the inactivated virus and antigenic similarity
between a circulating viral strain and the vaccine strain is
a decisive factor of vaccine’s efficacy [2]. The matrix protein
2 (M2) is a third and the smallest transmembrane integral
protein of the virus which, unlike HA and NA, is highly
conserved among influenza A strains [5]. M2 forms ion
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channels composed of tetramers of M2 and is essential for
efficient virus replication. It has been demonstrated else-
where that an extracellular part of the M2 protein (M2e)
consisting of 23 amino acids may serve as a vaccine target
and elicit production of neutralizing antibodies against
infection [6–8]. Several M2e conjugates, including M2e
fusion with an immunodominant epitope of hepatitis B
virus core protein provided a high degree of protection
against a lethal virus challenge in mice [7,8]. Judging from
these findings, recombinant M2e-based vaccine candidates
represent a promising alternative to the existing vaccines,
which are not adapted to continuous virus variability.
Our research is focused on the use of plants as biofac-
tories for the overproduction of vaccines and therapeutic
proteins. Plants represent inexpensive, environmentally
friendly sources of raw materials and can be grown any-
where locally without expensive fermentation equipment.
We have previously reported an expression system based
on capsid protein gene (CP) of cucumber mosaic virus
Ixora strain (CMV-Ix) placed under transcriptional con-
trol of potato virus X (PVX)-based vector. PVX-expressed
CMV CP formed virus-like particles which served as carri-
ers for heterologous antigens of Newcastle disease virus
(NDV) [9]. In this work, we applied our expression tool
toward the development of a plant-derived, M2e-based
vaccine candidate against avian influenza virus. Plant-
manufactured CMV capsids displaying M2e epitope
reacted to specific antibodies raised against synthetic
M2e peptide. Immunoreactive CMV CP-M2e protein
was also expressed to high levels in Escherichia coli cells
using Invitrogen’s pET151 expression vector. To the best
of our knowledge, this is the first report of the production
of a potential neutralizing epitope of avian influenza virus
in plants.
Materials and methods
Construction of recombinant plant virus
Consensus M2e epitope SLLTEVETPTRNE-
WECRCSDSSD, obtained by multiple alignment of differ-
ent reported H5N1 isolates of the virus was incorporated
into motif 5 of CMV Ixora CP by fusion PCR as described
in Natilla et al. [9]. Three PCR primers were made to per-
form the reaction:
1. Complementary primer to amplify the 5 0-terminus of
CMV-Ix CP upstream of the insertion together with
the 5 0 half of the M2e epitope (upper case M2e, small
case CMV CP): 5 0-TTCTAGTAGGAGTTTCCACTT
CAGTAAGAAGTGActcgagcgcatcgtcttttg-3 0. This pri-
mer was used with previously reported homologous
CMV CP primer LN10 [9].
2. Homologous primer to amplify the 3 0-terminus of CMV-
Ix CP downstream from the insertion together with the
3 0 half of M2e epitope (upper case M2e, small case
CMV CP): 5 0-ATGAATGGGAATGTAGATGTTCTG
ATTCTTCTGATacggatgagctggtactccatg-3 0. This pri-
mer was used with previously reported complimentary
CMV CP primer LN2 [9].
3. Complementary overlapping primer to anneal two PCR
products in one reaction and produce the complete M2e
epitope inserted into CMV CP: 5 0-CTACATTCCC
ATTCATTTCTAGTAGGAGTTTC-3 0.
Amplified PCR product comprising the M2e epitope
incorporated into motif 5 of CMV CP (Fig. 1a), was cloned
first into pCR TOPO II vector (Invitrogen) following by
subcloning into PVX-based vector pP2C2S (obtained by
Molecular Plant Pathology Laboratory from D. Baul-
combe, Sainsbury Laboratories, Norwich, England) as
described [9].
Transcript preparation and inoculation of plants
Plasmids were linearized using restriction enzyme SpeI,
and capped T7-RNA polymerase transcripts were gener-
ated from cDNA clones using Ambion’s T7 mMessage
Machine kit (Ambion, Austin, TX). The transcripts were
mechanically inoculated onto fully expanded leaves of
Nicotiana benthamiana.
Whole leaf squash blots
The procedure has been performed as described in
Hendy et al. [10] with minor modifications. Briefly, individ-
ual leaves from infected plants were immersed in liquid
nitrogen for 1–2 s. Leave were placed on a nitrocellulose
membrane and allowed to return to room temperature
for 5 min. Pressure was evenly applied over the leaf sur-
face for 30 min. Membranes were dried at room tempera-
ture for 10 min and then incubated in 5% w/v non-fat
milk powder in 1· PBS–0.05% Tween 20 for 1 h at room
temperature (RT) to prevent non-specific binding. The
membranes were then incubated with rabbit polyclonal
antibodies raised against M2e epitope diluted to 1:1000 in
blocking solution for 2 h at RT followed by incubation
with goat anti-rabbit IgG-alkaline phosphatase conjugate
(Sigma) for 2 h at RT. Blots were washed three times with
1· PBS–0.05% Tween 20 and developed with nitroblue tet-
razolium chloride (NBT) and bromo-chloro-indolyl phos-
phate (BCIP, Kirkegaard and Perry Laboratories, Inc.,
Gaithersburg, MD).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total nucleic acids were extracted using TRI Reagent
(Molecular Research Center, Inc., Cincinnati, OH) from
non-inoculated symptomatic leaves 5–7 days post-inocula-
tion (dpi). RT and PCR were performed in a single reaction
mixture utilizing an RT-PCR Titan One Tube kit as
described by the manufacturer (Roche Molecular Biochem-
icals, Chicago, IL) and the CMV CP-specific primer pair
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LN2/LN10. The PCR fragments were fractionated by elec-
trophoresis on a 0.8% agarose gel.
Analysis of protein expression by Western blot
Fifty to 100 mg of leaf tissues were homogenized in
Eppendorf tubes in 1· PBS buffer containing 1:100 dilution
of protease inhibitors cocktail (Sigma). After centrifuga-
tion for 10 min at 13,200 rpm (relative centrifugal force
of 16,110g, Eppendorf centrifuge model 5415D), the super-
natant was mixed with 2· Laemmli loading buffer and elec-
trophoresed on pre-cast Novex 10–20% Tris–Glycine gels
(Invitrogen), following by blotting onto a nitrocellulose
membrane (Invitrogen). Membranes were probed with
polyclonal antibodies to CMV (ATCC) or polyclonal anti-
bodies produced against synthetic M2e peptide. A synthetic
M2e peptide of the respective amino acid sequence SLLTE-
VETPTRNEWECRCSDSSD and rabbit polyclonal anti-
bodies were produced by Pacific Immunology Corp.,
Ramona, CA, according to the company protocols. Speci-
ficity of antibody and reactivity of the synthetic peptide
were tested in separate experiments by Western blot assays
(not shown). Reactions were developed with NBT/BCIP
(Kirkegaard and Perry Laboratories, Inc., Gaithersburg,
MD).
Direct M2-ELISA protocol for protein quantification
Fifty milligrams of leaf tissues were homogenized in
Eppendorf tubes in 400 ll of 1· PBS buffer containing
1:100 dilution of protease inhibitors cocktail (Sigma).
After centrifugation for 10 min at 13,200 rpm (relative
centrifugal force of 16,110g, centrifuge model 5415D
Eppendorf), ELISA plates were coated with 100 ll of
the resulting supernatant and incubated at 4 C over-
night. Different known concentrations of synthetic M2e
peptide, diluted in supernatant obtained in a similar
way from non-infected N. benthamiana plants, were used
Fig. 1. (a) Nucleotide (5 0–3 0) and amino acid sequence of the chimeric CMV-Ix CP gene with incorporated M2e epitope of avian influenza virus
(highlighted). (b and c) Predicted secondary structures of the wild type CMV CP subunit and hybrid CMV CP with M2e epitope, respectively. Arrows
indicate bH–bI loop (motif 5).
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as positive controls and a supernatant from non-infected
plant without addition of M2e peptide served as a nega-
tive control. After incubation plates were washed twice
by filling the wells with 200 ll of 1· PBS and shaking
for 3 min in Boekel Jitterbug Microplate Incubator Sha-
ker (Boekel Scientific). Antigen-coated wells were blocked
by adding 200 ll per well of blocking buffer, 5% non-fat
dry milk in 1· PBS. The plate was incubated for 2 h at
room temperature, washed twice with 1· PBS and loaded
with 1:1000 dilution of rabbit polyclonal antibodies to
the M2e peptide (Pacific Immunology) in blocking buffer.
Plates then were incubated 2 h at room temperature,
washed 5 times with 1· PBS and loaded with 1:5000 dilu-
tion of polyclonal goat anti-rabbit antibodies conjugated
to alkaline phosphatase (Sigma). Following 5 times thor-
ough washing, 100 ll of the substrate solution (p-nitro-
phenylphosphate, KPL) were dispensed into each well.
After sufficient color development the absorbance values
were read with Bio-Rad 680 microplate reader.
Protein expression in E. coli
CMV CP-M2e fusion gene as well as wild type (WT)
CMV CP were re-amplified using pCR TOPO II/CMV
CP-M2e and pCR TOPO II/CMV CP-WT plasmids as
templates and cloned into pET151 Directional TOPO
vector following manufacturer’s directions (Invitrogen).
Proteins were expressed using BL21 Star (DE3) One Shot
Chemically Competent Cells under recommended condi-
tions (Invitrogen). IPTG was added to a final concentra-
tion of 1 mM and induced cultures incubated for 4–6 h at
37 C. Samples were then pelleted by centrifugation,
resuspended in 500 ll of lysis buffer (50 mM potassium
phosphate, pH 7.8, 0.4 M NaCl, 0.1 M KCl, 10% glyc-
erol, 0.5% Triton X-100, and 10 mM imidazole) and trea-
ted as advised by manufacturer to separate soluble
protein from insoluble (Invitrogen). Insoluble protein
was further purified under denaturing conditions in 1 ml
of 8 M urea, 0.1 M NaH2PO4, 0.01 M Tris–HCl, pH
8.0, and 600 ll of cleared lysate was loaded onto pre-
equilibrated Ni–NTA spin columns designed for purifica-
tion of 6· His-tagged proteins from small-scale bacterial
expression cultures (Ni–NTA Spin Kit, Qiagen). Spin col-
umns were washed twice and protein eluted as described
by the manufacturer (Qiagen). Eluates were analyzed by
PAGE following by staining with SimplyBlue SafeStain
reagent (Invitrogen) or Western blot and probing with
specific antibodies.
Sequencing
All recombinant constructs and RT-PCR products
amplified from infected plants were sequenced on an
ABI-PRIZM 373A Genetic Analyzer at the DNA Sequenc-
ing Facility, Center for Biosystems Research, College Park,
MD. Sequence data were analyzed using Lasergene soft-
ware by DNASTAR (Madison, WI).
Results
Design of recombinant CMV CP-M2 constructs
The M2e epitope was engineered into the internal bH–bI
loop [11] of the CMVCP Ixora strain between glutamic acid
(E-195) and threonine (T-196), similar to the previously
described epitopes of Newcastle disease virus [9]. As pre-
dicted by automated proteomic server ExPASy at http://
swissmodel.expasy.org/ and reconstructed by molecular
graphics program (UCSF Chimera package, University of
California, San Francisco), addition of the M2e epitope
would further extend the bH–bI loop exposed on the sur-
face, enhancing its antigenic potential (Fig. 1b and c).
Symptoms and stability of the recombinant virus in plants
The recombinant PVX/CMV CP-M2e virus vector was
infectious and caused typical PVX symptoms of vein clear-
ing and chlorotic mosaic on leaves of inoculated N. benth-
amiana plants 5–7 days post inoculation (not shown). The
engineered virus remained stable and produced chimeric
CMV CP with H5N1 M2e epitope for two weeks post inoc-
ulation after which time the virus gradually reverted to
WT. The hybrid virus remained stable for the same period
of time after the second passage from transcript-inoculated
plants. The second passage, however, had to be carried out
from non-symptomatic transcript-inoculated plants 2–3
days post inoculation to preserve the predominantly
recombinant form of the virus in the inoculum. Expression
of CMV CP-M2e was monitored by Western blotting.
Squash blots
Whole leaf squash blots developed with antibodies spe-
cific to the M2e epitope showed that PVX-expressed
recombinant CMV CP-M2e protein is uniformly distrib-
uted and accumulated throughout the entire leaf tissue of
the infected plants (Fig. 2a and b).
RT-PCR
Total RNA samples extracted from virus-inoculated
plants were used for RT-PCRs with primers specific to
CMV CP and/or to the pP2C2S (PVX) sequence regions
surrounding the multiple cloning site of the virus-vector.
Gene-specific RT-PCR products indicated the presence of
recombinant CMV CP-M2e mRNA (Fig. 2c). RT-PCR
products were purified with MinElute Reaction Cleanup
Kit (Qiagen) and sequenced. The sequence was identical
to the original CMV CP-M2e construct obtained by fusion
PCR.
Expression of recombinant protein in plants
When clarified plant extracts were electrophoresed
through 10–20% Tris–Glycine gels, transferred to
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nitrocellulose membrane and probed with either CMV-
specific antibodies or antibodies specific to synthetic
M2e peptide, the expected size bands corresponding to
the CMV CP carrier fused to the M2e epitope were
clearly observed on the membranes (Fig. 3a and b) thus
demonstrating immunoreactivity of the recombinant
fusion protein. Recognition by M2e-specific antibodies
insured that the antigen inserted in bH–bI loop of
CMV CP is accessible and would likely elicit specific
immune response.
Using colorimetric M2e-ELISA assay, the amount of
recombinant CMV-M2e protein in an infected plant
extract was measured by comparison of the OD values at
405 nm with known concentrations of the synthetic M2e
peptide as described in Materials and methods. The esti-
mated amount of CMV-M2e was 6–8 lg/g of leaf tissue
(or 0.1% of total soluble protein).
Bacterial expression of CMV CP-M2e recombinant protein
Following expression in E. coli, recombinant proteins
were found to accumulate in inclusion bodies. Interest-
ingly, aggregates of protein in inclusion bodies, which
were not yet treated with denaturing 8 M urea buffer,
were immunoreactive with both CMV and M2e antibod-
ies (not shown). When solubilized inclusion bodies were
purified on high affinity Ni–NTA spin columns and elec-
trophoresed through 10–20% Tris–Glycine gels, two sin-
gle bands, corresponding to near homogeneous proteins
(from constructs pET151/CMV CP-WT and pET151/
CMV CP-M2e, respectively) fused to the expression vec-
tor’s elements (polyhistidine region, V5 epitope and TEV
recognition site), were present on both SimplyBlue
reagent-stained gels and membranes probed with pro-
tein-specific antibodies (Fig. 3). Concentration of recom-
binant CMV CP-M2e protein, affinity-purified from a
small-scale 5 ml culture was as high as 118 lg/ml, as
determined by Bradford assay.
Discussion
This study is a continuation of our work on the PVX/
CMV CP expression system. We demonstrated previously
that coat protein of CMV-Ix expressed from heterologous
PVX virus is capable of forming stable virus-like particles
(VLP) that can accommodate incorporation of useful for-
eign epitopes into surface-displayed bH–bI loop (motif 5)
[9]. Here we provide evidence that the CMV capsid can
be used for expression in plants of the external domain of
avian influenza A virus M2 protein. VLP-displayed M2e
epitope remained immunoreactive, which was demon-
strated by its binding to the epitope-specific antibody.
Whole leaf squash blot analysis of plants infected with
recombinant PVX/CMV CP-M2e virus showed that
CMV CP-M2e antigen was distributed throughout the
entire infected leaf tissue and thus accumulates in plants
systemically as does the virus itself.
In addition to transient expression in plants, 6·his-tagged
CMV CP-M2e was efficiently expressed in E. coli and
recognized by both CMV- and M2e-specific antibodies.
VLPs are increasingly used as both vaccine candidates
against parental viruses and as stabilizers and adjuvants
for inserted foreign antigens to enhance broad immune
response to fused epitopes. Recent outbreaks of HPAIV,
highly pathogenic avian influenza virus subtype H5N1 that
normally occurs in domestic fowl but was also found in
migratory birds, different mammals and humans, created
a real threat of pandemic and an urgent need to develop
a vaccine strategy fundamentally different from existing
vaccine routes. The current flu vaccines are based on inac-
tivated or live attenuated (weakened) viruses regularly
updated to incorporate antigens derived from major strains
in circulation [12]. Plasmid-based reverse-genetics
approach that produce infectious viruses from cDNA cop-
ies of its genes, is rapidly emerging as an alternative tech-
nology to produce any needed viral mutant by genetic
reassortment in vitro [13]. The M2 protein is a highly
Fig. 2. (a and b) Whole leaf squash blots probed with antibodies to the M2e epitope. (a) Plant infected with recombinant PVX containing a wild type
(WT) gene of CMV-Ix coat protein (CP); (b) plant infected with PVX containing the CMV CP-M2e fusion. (c) RT-PCR products amplified from plants
infected with recombinant PVX/CMV CP- M2e virus using CMV CP-specific primers LN2/LN10. M, Lambda DNA EcoRI/HindIII marker (Promega):
2, 1.5, 1.3, 0.9, 0.8, and 0.5 kb. Lanes 1 and 2, RT-PCRs from two different plants infected with PVX/CMVCP-M2e virus; lane 3, RT-PCR from plant
infected with WT PVX.
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conserved antigen that has remained nearly unchanged
over several decades. Although it is weakly immunogenic,
its potential as a vaccine candidate is supported by studies
showing that the M2e fusion to another protein can elicit
protective antibody response and most importantly, by
the antigen’s stability, which would lessen the burden of
yearly updating influenza vaccines to reflect the current cir-
culating strain.
The first study aimed to develop M2-based influenza
vaccine used translational fusion to hepatitis B virus core
(HBc) antigen as an adjuvant [7]. The antigen was
expressed in bacteria and provided 90–100% protection
against a lethal virus challenge. The M2e-based vaccine
was further optimized by increasing amounts of M2e cop-
ies linked to the N-terminus of the HBc [14]. Preclinical
studies of M2e synthetic peptide conjugated with keyhole
limpet hemocyanin (KLH) demonstrated protection
against lethal challenge of H1N1 or H3N1 virus in mice
[6]. M2e antisera cross-reacted with a wide range of human
influenza A strains.
To our knowledge, prior to this study there were no
attempts to explore plant systems for the expression of
HPAIV antigens. Meanwhile, in planta agricultural scale
production of the viral M2e epitope, genetically fused to
appropriate carrier molecule to enhance its immunogenic-
ity, would represent a new and unconventional strategy
for development of vaccine candidate against the virus.
In addition to the expression system described in this work,
one of the natural carriers-adjuvants previously tested in
plants is non-toxic B subunit of cholera toxin (CTB). Our
earlier results on using CTB as a carrier for neutralizing
epitope of hepatitis C virus demonstrated that CTB tran-
siently expressed in plants retained its functional activity,
formed pentamers and contributed to the immune response
Fig. 3. (a and b) Western blots of extractions from PVX/CMV CP-M2e plants probed with CMV (a) and M2e (b) antibodies. M, ColorBurst Molecular
weights (kDa) protein marker (Sigma): 40, 30, 20, 13, and 8; lane 1, purified preparation of WT CMV Ixora virus; lane 2, M2e synthetic peptide, lanes 3–5,
different plants infected with recombinant PVX/CMV CP-M2e virus; lane 6, uninfected control plant. Arrows on the left indicate position of positive
controls; arrows on the right indicate positions of expected CMV CP/M2e bands. (c–e) expression of the CMV CP-M2e antigen in bacteria. (c) Gel was
stained with SimplyBlue SafeStain (Invitrogen). M, ColorBurst Molecular weights (kDa) protein marker (Sigma), 65, 40, 30, 20, 13, and 8; lane 1, 2 lg
of purified preparation of WT CMV Ixora virus; lane 2, 10 ll of IPTG-induced, 6· His-tagged preparation of CMV CP WT expressed in E. coli and
purified using Ni–NTA spin column; lane 3, 10 ll of IPTG-induced, 6· His-tagged preparation of CMV CP/M2e expressed in E. coli and purified using
Ni–NTA spin column; lane 4, same as in 3, uninduced sample. (d and e) Western blots of recombinant proteins expressed in E. coli, and probed with CMV
antibodies (d) or M2e antibodies (e). M, ColorBurst Molecular weights (kDa) protein marker (Sigma), lane 1, 500 ng of purified preparation of WT CMV
Ixora virus; lane 2, 2 lg of synthetic M2e peptide; lane 3, IPTG-induced 6·His-tagged preparation of CMV CPWT expressed in E. coli and purified using
Ni–NTA spin column, 1:10 dilution of the sample used for SimplyBlue stained gel, 2 ll loaded; lane 4, IPTG-induced, 6· His-tagged preparation of
CMV CP/M2e protein expressed in E. coli and purified using Ni–NTA spin column, 1:10 dilution of the sample used for SimplyBlue stained gel, 2 ll
loaded. Arrow indicates position of M2e positive control.
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against fused HCV epitope [15]. Perhaps using CTB as a
carrier for M2e, that is four amino acids shorter than
Hypervariable Region 1 of HCV, could also result in a sta-
ble and effective antigenic module eliciting immune
response against viral protein.
Expression in E. coli was conducted to assess an antige-
nicity of the recombinant protein prior to large-scale pro-
duction in plants, that is, resultant protein will be used
for immunization and screening of generated antibodies
against the M2e epitope fused to CMV capsid. It was also
important to demonstrate applicability of the protein
production in both plant and bacterial systems. The
CMV CP-M2e protein produced in E. coli BL21 Star
(DE3) accumulated in the form of inclusion bodies, which
were immunoreactive themselves before solubilization in
denaturing buffer and affinity purification of the His-tagged
protein. It was reported elsewhere for bacterially expressed
antigen of classical swine fever virus (CSFV), that inclusion
bodies can induce both systemic and mucosal responses
when administered orally and thus be a convenient alterna-
tive to other antigen delivery systems as well as to a neces-
sity of mucosal adjuvant [16]. Although it is unknown in
what form the conglomerates of CMV CP-M2e protein
exist in inclusion bodies, the fact that they are highly
immunoreactive could possibly mean that the antigen
may well provoke immune response in vivo without any
need of further purification from insoluble precursor.
The investigation of new insights and technologies in the
field of traditional vaccination against influenza viruses are
urgently needed to both reduce the cost of current vaccines
and to explore the entirely novel strategies of vaccine devel-
opment. Plant-derived vaccines raised a great hope of
availability of the preparations to developing countries,
lower production costs and increased safety standards.
This initial study demonstrates the feasibility of expression
of an immunogenic epitope of influenza A virus in plants
and the prospects of using a plant-virus based carrier as
an alternative to the previously reported M2e conjugate
vaccines.
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